SECsense Logo

IceCure Medical Ltd. Appoints New Director in Key 6-K Report – December 2024 Insights

$ICCM
Form 6-K
Filed on: 2024-12-30
Source
IceCure Medical Ltd. Appoints New Director in Key 6-K Report – December 2024 Insights

Based on the provided section of the financial report for IceCure Medical Ltd., here are the key insights and information extracted:

  1. Document Type: This is a Form 6-K report filed by a foreign private issuer, which is typically used to report significant events or information that may be of interest to shareholders.
  2. Date of Filing: The report was submitted on December 30, 2024, referencing events that occurred on December 23, 2024.
  3. Company Information:
  • Name: IceCure Medical Ltd.
  • Principal Office Address: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel.
  1. Board Appointment:
  • New Director: Mr. Li Haixiang has been appointed to the Board of Directors until the next annual general meeting.
  • Background: Mr. Haixiang is the founder and managing partner of Virtus Inspire Ventures, a venture capital firm. He has extensive experience in finance, investment, and capital markets.
  1. Shareholder Control: Mr. Haixiang has voting and dispositive power over the shares held by Epoch Partner Investments Ltd., which is identified as the controlling shareholder of IceCure Medical Ltd.
  2. Other Directorships: Mr. Haixiang holds multiple directorships, including:
  • Independent non-executive director at AVO Insurance Company Holding since August 2018.
  • Independent non-executive director at FUTU Holding Limited (NASDAQ: FUTU) since March 2019.
  • Numerous sole directorships in various companies, highlighting his extensive governance experience.
  1. Qualifications: Mr. Haixiang holds a Bachelor’s degree from South China University of Technology and a Master’s degree from China Europe International Business School.
  2. Incorporation by Reference: The report is incorporated by reference into the company's Registration Statements on Form F-3 and Form S-8, indicating that this filing may have implications for other securities offerings by the company.
  3. Signatory: The report is signed by Eyal Shamir, the Chief Executive Officer of IceCure Medical Ltd., indicating official approval and acknowledgment of the contents.

This report is significant as it outlines a key change in the board of directors and highlights the control structure of the company, which may be of interest to current and potential investors.